IT202200010439A1 - Composizione comprendente acido nevronico e beta-cariofillene nel trattamento della mucosite - Google Patents

Composizione comprendente acido nevronico e beta-cariofillene nel trattamento della mucosite Download PDF

Info

Publication number
IT202200010439A1
IT202200010439A1 IT102022000010439A IT202200010439A IT202200010439A1 IT 202200010439 A1 IT202200010439 A1 IT 202200010439A1 IT 102022000010439 A IT102022000010439 A IT 102022000010439A IT 202200010439 A IT202200010439 A IT 202200010439A IT 202200010439 A1 IT202200010439 A1 IT 202200010439A1
Authority
IT
Italy
Prior art keywords
caryophyllene
mucositis
beta
treatment
composition including
Prior art date
Application number
IT102022000010439A
Other languages
English (en)
Inventor
Fabio Ignazio Donato
Federica Taryn Parascandolo
Original Assignee
Anatek Health Italia S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anatek Health Italia S R L filed Critical Anatek Health Italia S R L
Priority to IT102022000010439A priority Critical patent/IT202200010439A1/it
Publication of IT202200010439A1 publication Critical patent/IT202200010439A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
IT102022000010439A 2022-05-19 2022-05-19 Composizione comprendente acido nevronico e beta-cariofillene nel trattamento della mucosite IT202200010439A1 (it)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT102022000010439A IT202200010439A1 (it) 2022-05-19 2022-05-19 Composizione comprendente acido nevronico e beta-cariofillene nel trattamento della mucosite

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102022000010439A IT202200010439A1 (it) 2022-05-19 2022-05-19 Composizione comprendente acido nevronico e beta-cariofillene nel trattamento della mucosite

Publications (1)

Publication Number Publication Date
IT202200010439A1 true IT202200010439A1 (it) 2023-11-19

Family

ID=82942722

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102022000010439A IT202200010439A1 (it) 2022-05-19 2022-05-19 Composizione comprendente acido nevronico e beta-cariofillene nel trattamento della mucosite

Country Status (1)

Country Link
IT (1) IT202200010439A1 (it)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000321A1 (en) * 2003-06-25 2005-01-06 Bioplax Limited Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas
WO2015056196A1 (en) * 2013-10-16 2015-04-23 Orahealth Corporation Treating mucosal lesions with hyaluronan delivered from an adhering troche
EP3437638A1 (en) * 2017-08-01 2019-02-06 Inpha Duemila S.r.l. Nervonic acid and curcumin for the treatment of pathologies associated with peripheral nerves trophism alterations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000321A1 (en) * 2003-06-25 2005-01-06 Bioplax Limited Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas
WO2015056196A1 (en) * 2013-10-16 2015-04-23 Orahealth Corporation Treating mucosal lesions with hyaluronan delivered from an adhering troche
EP3437638A1 (en) * 2017-08-01 2019-02-06 Inpha Duemila S.r.l. Nervonic acid and curcumin for the treatment of pathologies associated with peripheral nerves trophism alterations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AL-MAWERI SADEQ ALI ET AL: "Efficacy of hyaluronic acid for recurrent aphthous stomatitis: a systematic review of clinical trials", CLINICAL ORAL INVESTIGATIONS, SPRINGER, BERLIN, DE, vol. 25, no. 12, 20 September 2021 (2021-09-20), pages 6561 - 6570, XP037623114, ISSN: 1432-6981, [retrieved on 20210920], DOI: 10.1007/S00784-021-04180-4 *
DA CRUZ CAMPOS MARIA ET AL: "Induced oral mucositis in Wistar rats treated with different drugs: Preventive potential in cytokine production", MOLECULAR AND CLINICAL ONCOLOGY, vol. 14, no. 6, 27 April 2021 (2021-04-27), GR, XP093005594, ISSN: 2049-9450, DOI: 10.3892/mco.2021.2289 *
EMINAGIC DZENANA ET AL: "Efficacy and safety of local lysozyme treatment in patients with oral mucositis after chemotherapy and radiotherapy", ACTA PHARMACEUTICA, vol. 69, no. 4, 21 October 2019 (2019-10-21), pages 695 - 704, XP093005591, DOI: 10.2478/acph-2019-0053 *
GIUSEPPE COLELLA ET AL: "A translational journey on the efficacy of hyaluronic acid in the prevention of oral mucositis: Results of a phase 2 trial", JOURNAL OF ORAL PATHOLOGY AND MEDICINE,, vol. 48, no. Supplement 1, 1 April 2019 (2019-04-01), pages 46, XP009518534, ISSN: 1600-0714 *
KLAUDYNA FIDYT ET AL: "β -caryophyllene and β -caryophyllene oxide-natural compounds of anticancer and analgesic properties", CANCER MEDICINE, vol. 5, no. 10, 1 October 2016 (2016-10-01), GB, pages 3007 - 3017, XP055525698, ISSN: 2045-7634, DOI: 10.1002/cam4.816 *
PICCIOLO GIACOMO ET AL: "[beta]-Caryophyllene Reduces the Inflammatory Phenotype of Periodontal Cells by Targeting CB2 Receptors", BIOMEDICINES, vol. 8, no. 6, 17 June 2020 (2020-06-17), pages 164, XP093005596, DOI: 10.3390/biomedicines8060164 *
SARGENT J R ET AL: "Nervonic acid and demyelinating disease", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 42, no. 4, 1 April 1994 (1994-04-01), pages 237 - 242, XP023027657, ISSN: 0306-9877, [retrieved on 19940401], DOI: 10.1016/0306-9877(94)90122-8 *

Similar Documents

Publication Publication Date Title
SV2011003828A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
CL2017003218A1 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
BR112015019440A8 (pt) curativo regulável, kit, uso e método para fortalecimento da pele
ECSP10010446A (es) Uso de ranolazina para el tratamiento del dolor
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
MX2019004402A (es) Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
CL2017001913A1 (es) Composición tópica curativa
IT202200010439A1 (it) Composizione comprendente acido nevronico e beta-cariofillene nel trattamento della mucosite
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
BR112019012084A2 (pt) uso médico de interferon-lambda para o tratamento de fibrose
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2022002239A1 (es) Tafoxiparina para el tratamiento de la preeclampsia
BR112021009616A8 (pt) Composição cicatrizante que compreende água eletrolisada e máscara de aplicação cutânea
IL272253A (en) Preparations and methods for treating inflammatory conditions of the skin
BR112015022591A2 (pt) componente para fornecer suporte estrutural, método para suportar uma massa, e, método para reduzir um fio
ES2970423T3 (es) Esfingomielinasa ácida humana recombinante para su uso en el tratamiento de afecciones óseas anormales en pacientes con deficiencia de esfingomielinasa ácida
TWI801006B (zh) 紅肉蘋果和櫻桃李組合物及其在抗血栓方面的應用
DOP2022000058A (es) Anticuerpos contra el factor de las células madre y métodos de uso de ellos
IT202200009101A1 (it) Composizione antiossidante per prevenire e trattare stati infiammatori delle vie respiratorie in particolare dei polmoni
BR112022021423A2 (pt) Uso de proteína surfactante d para tratar infecções virais
IT202200006161A1 (it) Forms and compositions of sodium chenodeoxycholate
IT202200010115A1 (it) Composizione per la prevenzione e il trattamento di malattie cutanee su base infiammatoria in particolare associate ad invecchiamento cutaneo
IT202200007811A1 (it) Nuova composizione per l’uso nel trattamento di ferite
ES1294925Y (es) Pieza prefabricada para la construccion de escaleras y bancadas